EP2943185
HÆGLOSANDI SAMSETNINGAR AF LÓRASEPAMI
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
9.1.2014EP published:
18.11.2020EP application number:
14702977.1
EP translation filed:
17.2.2021Grant published:
15.3.2021EPO information:
European Patent Register
Max expiry date:
8.1.2034Expiry date:
8.1.2027Next due date:
31.1.2027
Title:
SUSTAINED RELEASE FORMULATIONS OF LORAZEPAM
Timeline
Today
9.1.2014EP application
18.11.2020EP Publication
17.2.2021Translation submitted
15.3.2021Registration published
8.1.2027Expires
Owner
Name:
Edgemont Pharmaceuticals, LLC Liquidating TrustAddress:
1037 Raymond Blvd., Suite 1520, 07102, Newark, NJ, US
Inventor
Name:
SALTEL, Douglas A.Address:
Austin, Texas 78746, US
Name:
VACHON, MichaelAddress:
Austin, Texas 78746, US
Agent
Name:
G.H. Sigurgeirsson ehf.Address:
Borgartúni 26, 105, Reykjavík,
Priority
Number:
201361750797 PDate:
9.1.2013Country:
US
Number:
201361762833 PDate:
8.2.2013Country:
US
Classification
Categories:
A61K 9/16, A61K 9/50, A61K 31/5513, A61P 25/22, A61P 25/24
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 8.2.2021
Expires: 8.1.2022
Payer: Árnason Faktor ehf.
Number: 9
Paid: 28.12.2021
Expires: 8.1.2023
Payer: Árnason Faktor ehf.
Number: 10
Paid: 13.12.2022
Expires: 8.1.2024
Payer: Árnason Faktor ehf.
Number: 11
Paid: 18.12.2023
Expires: 8.1.2025
Payer: Árnason Faktor ehf.
Number: 12
Paid: 24.1.2025
Expires: 8.1.2026
Payer: Árnason Faktor ehf.
Number: 13
Paid: 7.1.2026
Expires: 8.1.2027
Payer: Árnason Faktor ehf.